Regarding the management of chronic nasal polyposis, all of the following are evidence-based treatment modalities EXCEPT:

Explanation

## Management of Chronic Nasal Polyposis ### Correct Answer: Systemic Antihistamines as Monotherapy **Key Point:** Antihistamines have NO proven efficacy as monotherapy for nasal polyps. They may help with concurrent allergic rhinitis symptoms but do NOT control polyp growth or prevent recurrence. ### Evidence-Based Treatment Algorithm ```mermaid flowchart TD A[Chronic Nasal Polyposis]:::outcome --> B{Symptomatic?}:::decision B -->|Yes| C[Topical intranasal corticosteroid spray]:::action C --> D{Response adequate?}:::decision D -->|Yes| E[Continue maintenance therapy]:::action D -->|No| F[Add oral corticosteroid short course]:::action F --> G{Recurrent or refractory?}:::decision G -->|Yes| H[FESS with complete polyp removal]:::action G -->|No| I[Continue topical therapy]:::action B -->|No| J[Observation, address risk factors]:::action ``` ### Comparison of Treatment Modalities | Modality | Evidence | Role | Limitation | |----------|----------|------|------------| | **Topical intranasal corticosteroid spray** | Strong | First-line, long-term maintenance | Slow onset (2–4 weeks) | | **Oral corticosteroids (short course)** | Moderate | Acute exacerbation, pre-op optimization | Risk of systemic side effects with prolonged use | | **FESS with polyp removal** | Strong | Recurrent/refractory polyps, CRS with polyps | Recurrence rate 10–30% without adjuvant therapy | | **Systemic antihistamines** | Weak/None | Adjunct for allergic rhinitis symptoms only | NO effect on polyp growth or control | | **Leukotriene receptor antagonists** | Weak | May help in aspirin-sensitive polyps | Limited evidence | | **Biologic agents (dupilumab)** | Emerging | Moderate-to-severe eosinophilic polyps | Expensive, not first-line | ### High-Yield Facts **Key Point:** The stepwise approach to nasal polyp management is: 1. **First-line:** Topical intranasal corticosteroid spray (fluticasone, mometasone, budesonide) 2. **Adjunct/Acute:** Short course of oral corticosteroids (prednisolone 0.5–1 mg/kg/day × 5–14 days) 3. **Refractory/Recurrent:** FESS with complete polyp removal + post-operative topical corticosteroid 4. **Severe eosinophilic:** Biologic agents (dupilumab, mepolizumab) **Warning:** Antihistamines are often mistakenly prescribed for nasal polyps, especially if concurrent allergic rhinitis exists. While they may provide symptomatic relief of itching or sneezing, they do NOT address polyp pathology and should NOT be used as monotherapy. ### Clinical Pearl **Samter's Triad (Aspirin-Exacerbated Respiratory Disease):** - Chronic rhinosinusitis with nasal polyps - Asthma - Reaction to NSAIDs/aspirin - Management: Avoid NSAIDs, use topical/oral corticosteroids, consider aspirin desensitization ### Why Antihistamines Fail Nasal polyps are primarily driven by: - Th2-mediated inflammation (IL-4, IL-5, IL-13) - Eosinophilic infiltration - Mast cell activation (but antihistamines alone are insufficient) Corticosteroids suppress this cascade; antihistamines only block histamine receptors and do not address the underlying inflammatory milieu. [cite:Scott-Brown's Otorhinolaryngology Ch 5; EPOS 2020 Guidelines]